跳至主要内容
临床试验/NCT07127757
NCT07127757招募中不适用

Clinical Evaluation of Visual Outcomes With the Wavelight Plus Excimer Laser in Normal and Dim Lighting

Laser Defined Vision1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年8月28日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50
试验地点
1
主要终点
% of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

研究概览

简要总结

This study is a single-site, single-arm, prospective, observational study of subject satisfaction, quality of vision, and quality of life after bilateral LASIK surgery. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the adapted PROWL and Low Luminance Questionnaire (LLQ-32) Questionnaire.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must be able to understand and sign an IRB approved Informed consent form
  • Willing and able to attend all scheduled study visits as required per protocol
  • Minimum of 18 years of age
  • Myopia up to -8.00 D, astigmatism up to -3.00 D, with SE more than -1.00D and up to -9.00D, based on Sightmap measured refraction
  • Best corrected photopic distance visual acuity of 20/20-2 or better (≤ 0.04 logMAR)
  • Mesopic pupil size ≥ 4.5mm
  • Less than 0.75 D manifest refraction spherical equivalent difference between Sightmap refraction and subjective manifest refraction
  • Stable refraction (within ± 0.50 D) as determined by manifest refraction spherical equivalent for a minimum of 12 months prior to surgery, verified by consecutive subjective refractions or medical records or prescription history
  • If currently wearing contact lenses:
  • Soft CTL wearers discontinue for minimum 3 days prior to first refraction
  • RGP or toric soft CTL wearers discontinue for ≥2 weeks prior to first refraction

排除标准

  • Subjects who are pregnant or nursing
  • Acute or chronic disease or illness that would increase the operative risk or confound the outcomes of the study
  • Patients with flap complications
  • Systemic medications that may confound the outcome of the study or increase the risk to the subject.
  • Ocular condition (other than high myopia) that may predispose the subject to future complications, such as ectasia
  • History or evidence of active or inactive corneal disease (e.g., herpes simplex keratitis, herpes zoster keratitis, recurrent corneal erosion syndrome, corneal dystrophy)
  • Evidence of retinal vascular disease
  • Keratoconus or Keratoconus suspect
  • Glaucoma or glaucoma suspect by exam findings and/or family history
  • Previous intraocular or corneal surgery
  • Predicted residual stromal bed thickness < 250 μm
  • Intended to have monovision treatment
  • Participation in other current clinical trials

结局指标

主要结局

% of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

时间窗: 3 months postoperatively

% of eyes with UDVA of 20/10, 20/12.5, 20/16 and 20/20 in mesopic conditions at 3 months (monocular and binocular)

时间窗: 3 months postoperatively

% of eyes with CDVA of 20/10, 20/12.5, 20/16 and 20/20 in photopic conditions at 3 months (monocular and binocular)

时间窗: 3 months postoperatively

次要结局

  • % of eyes with absolute MRSE within +/- 0.25, 0.50, 0.75, and 1.00D at 3 months(3 months postoperatively)
  • Patient-Reported Outcomes with the modified PROWL Questionnaire and Low Luminance Questionnaire (LLQ-32) at 3 months(3 months postoperatively)
  • % of eyes with lines gained/lost lines (post-up UDVA VS pre-op CDVA)(3 months postoperatively)
  • % of eyes that achieved manifest refraction cylinder within +/- 0.25, 0.50, 0.75, and 1.00D at 3 months(3 months postoperatively)
  • % of eyes that achieve UDVA equal to or better than preoperative CDVA(3 months postoperatively)

研究者

发起方
Laser Defined Vision
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验